A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease.

ABSTRACT: Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous pathophysiological changes that develop years before the onset of clinical symptoms. These preclinical changes have generated considerable interest in identifying markers for the pathophysiological mechanisms linked to AD and AD-related disorders (ADRD). On the basis of our prior work integrating cerebrospinal fluid (CSF) and brain proteome networks, we developed a reliable and high-throughput mass spectrometry-selected reaction monitoring assay that targets 48 key proteins altered in CSF. To test the diagnostic utility of these proteins and compare them with existing AD biomarkers, CSF collected at baseline visits was assayed from 706 participants recruited from the Alzheimer's Disease Neuroimaging Initiative. We fo

SUBMITTER: Haque R 

PROVIDER: S-EPMC10880442 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature